IMMUNOHISTOCHEMICAL EXPRESSION OF MATRIX METALLOPROTEINASE-1 (MMP-1) IN DIFFERENT TYPES OF BREAST CARCINOMA AND ITS COMPARISON WITH ER/PER AND HER2/neu
AbstractBackground: Breast cancer is a complex disease that comprises of various biological sub-types with different natural history. Matrix metalloproteinase-1(MMP-1) expression has been reported to inversely correlate with the survival. The current study was conducted to classify breast cancer into four subtypes based on IHC, to assess the immunohistochemical expression of MMP-1 in primary breast carcinoma, to compare its expression with ER/PR and HER2/neu. Methods: A descriptive study was conducted on 100 mastectomy specimens of breast carcinoma after being fixed in 10% formalin at Department of Histopathology, University of Health Sciences Lahore. Sections were taken on frosted slides for H&E and on lysine coated slides for immunohistochemistry (IHC). Haematoxylin and eosin (H&E) and IHC for oestrogen receptor/progesterone receptor (ER/PR), HER2/neu and Matrix metalloproteinase (MMP-1) were performed according to protocol. Results: The mean age was 48.44±11.79 Years (ranging 25 to 90 years). 97 cases were of Invasive ductal carcinoma (IDC) type, two showed the features of invasive lobular carcinoma and only one case was found to be of mucinous type, 19 cases were found to be in grade I, 74 in grade II and seven cases were in grade III. Breast cancer has been classified into four major groups based on IHC profile ER/PR and HER2/neu expression. The groups were: Triple positive, ER/PR+, HER2-, ER/PR-, HER2/neu+ and triple negative) cases. Among 100 cases of breast cancer, 9 were of triple positive type, (ER/PR +, HER2/neu+), 28 cases were of ER/PR +, HER2- type, 19 were ER/PR-, HER2/neu +ve and 44 cases were of triple negative type (ER/PR-, HER2/neu-ve). 13 cases were of score 1 MMP-1out of which 7 (25.0%) were ER/PR+, HER2-, 1 (5.3%) case was ER/PR-, HER2/neu +ve and 5 (11.4%) cases were triple negative. Among 30 cases of MMP-1 score 4, 5(55.6%) cases were of triple positive type, 3 (10.7%) cases were of ER/PR +, HER 2/neu-ve type, 12(63.2%) cases were of ER/PR-, HER 2/neu+ve type, and 10 (22.7%) cases were of triple negative type. A significant p-value of <0.05 was obtained. Conclusions: Among four IHC based subtypes, most frequent were triple negative breast cancers which showed high IHC score of MMP-I which is reported to be an important marker for metastatic potential in breast carcinoma.
Sun YS, Zhao Z, Yang ZN, Xu F, Lu HJ, Zhu ZY, et al. Risk factors and preventions of breast cancer. Int J Biol Sci 2017;13(11):1387–97.
Torre LA, Islami F, Siegel RL, Ward EM, Jemal A. Global cancer in women: burden and trends. Cancer Epidemiol Biomarkers Prev 2017;26(4):444–57.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394–424.
Rasool S, Iqbal M, Siddiqui A, Ahsan R, Mukhtar S, Naqvi S. Knowledge, Attitude, Practice towards Breast Cancer and Breast Self-examination among Female Undergraduate Students in Karachi, Pakistan. J Adv Med Med Res 2019;10:1–1.
Cao SS, Lu CT. Recent perspectives of breast cancer prognosis and predictive factors. Oncol Lett 2016;12(5):3674–8.
Vrieling C, van Werkhoven E, Maingon P, Poortmans P, Weltens C, Fourquet A, et al. Prognostic factors for local control in breast cancer after long-term follow-up in the EORTC boost vs no boost trial: a randomized clinical trial. JAMA Oncol 2017;3(1):42–8.
Miller KD. Immunocytochemical techniques. In: Bancroft JD, Gamble M, editors. Theory and practice of histological techniques. 5th ed. New York. Churchill Livingstone. 2002; p.423–5.
Parise CA, Caggiano V. Breast cancer survival defined by the ER/PR/HER2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers. J Cancer Epidemiol 2014;2014:469251.
Boström P, Söderström M, Vahlberg T, Söderström KO, Roberts PJ, Carpén O, et al. MMP-1 expression has an independent prognostic value in breast cancer. BMC Cancer 2011;11(1):1–8.
Bancroft JD, Gamble M, editors. Theory and practice of histological techniques. Elsevier health sciences; 2008.
Chand P, Garg A, Singla V, Rani N. Evaluation of immunohistochemical profile of breast cancer for prognostics and therapeutic use. Niger J Surg 2018;24(2):100–6.
Mir MA, Manzoor F, Singh B, Raja W, Jeelani S, Zargar WA, et al. Clinicopathological Profile of Breast Cancer Patients at a Tertiary Care Hospital in Kashmir Valley. Surg Sci 2017;8(3):162–8.
Asrar I, Usman M, Javeed S, Anwar A, Naseem N, Nagi AH, et al. Breast carcinoma: A clinicopathological study of 90 cases. Prof Med J 2020;27(2):381–7.
Naqvi SR, Farhat K, Naqvi SS, Rashid MM, Sheikh IA, Ali M. Breast cancer: clinical and histopathological features at combined military hospital Rawalpindi. Pak Armed Forces Med J 2017;67(4):540–4.
Makki J. Diversity of Breast Carcinoma: Histological Subtypes and Clinical Relevance. Clin Med Insights Pathol 2015;8:23–31.
Rehman F, Nagi AH, Hussain M. Immunohistochemical expression and correlation of mammaglobin with the grading system of breast carcinoma. Indian J Pathol Microbiol 2010;53(4):619–23.
Oluogun WA, Adedokun KA, Oyenike MA, Adeyeba OA. Histological classification, grading, staging, and prognostic indexing of female breast cancer in an African population: A 10-year retrospective study. Int J Health Sci 2019;13(4):3–9.
Wang QM, Lv L, Tang Y, Zhang L, Wang LF. MMP 1 is overexpressed in triple negative breast cancer tissues and the knockdown of MMP 1 expression inhibits tumor cell malignant behaviors in vitro. Oncol Lett 2019;17(2):1732–40.